FINWIRES · TerminalLIVE
FINWIRES

德斯賈丁斯集團質疑高油價是否會削弱加拿大消費者的購買力。

-- 德斯賈丁斯集團的蘭德爾·巴特利特指出,與伊朗的衝突導致全球油價飆升,推高了燃料和化肥價格,同時運輸瓶頸問題再次出現,引發了人們對供應鏈壓力可能再次推高所有商品價格的擔憂。 巴特利特表示,這次能源價格衝擊可能會對加拿大消費者造成壓力,儘管他們在與美國的貿易戰期間一直保持著韌性。 巴特利特認為,本已面臨巨大財務壓力的低收入家庭最難承受通膨的再次加速。但他同時指出,與較富裕的家庭相比,他們短期內受運輸成本上漲的影響較小。 此外,巴特利特指出,消費稅/統一銷售稅抵免額的增加——即在伊朗衝突前就已計劃的加拿大食品和必需品福利——應該足以抵消2026年中期能源價格上漲對消費的影響。 巴特利特表示,減稅、價格管制以及增加對經濟最脆弱家庭的收入轉移支付,都是各級政府可以用來為加拿大人提供額外援助的手段。但他補充說,所有這些措施都需要付出代價,而且有些代價更高。 「為了抵消能源價格上漲帶來的通膨影響,政策選擇需要在提供廣泛支持和幫助最需要幫助的加拿大人之間取得平衡,同時也要關注財政的可持續性,」巴特利特指出。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703